Parenteral formulations of dopamine agonists

Abstract

This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of international application no. PCT / U.S.09 / 00268, filed Jan. 14, 2009, which is a continuation-in-part of prior U.S. application Ser. No. 12 / 144,620, filed Jun. 23, 2008. This application is also a continuation-in-part of prior U.S. application Ser. No. 12 / 144,620, filed Jun. 23, 2008. The application claims priority under 35 U.S.C. §119 of U.S. provisional application No. 61 / 020,930, filed Jan. 14, 2008 and U.S. provisional application No. 60 / 945,562 filed Jun. 21, 2007. Each of the foregoing applications is hereby incorporated herein by reference in its entirety.FIELD OF THE INVENTION[0002]This invention relates to pharmaceutical parenteral dosage formulations comprising dopamine agonists, alone or in combination with peripheral acting agents useful for treatment of metabolic disorders, and to processes for preparing such formulations and methods of treatment using such formulations.BACKGROUND OF THE ...

AI Technical Summary

Benefits of technology

[0017]In another embodiment, the invention provides a method for reducing elevated cardiovascular-related inflammatory factors or cardiovascular disease or key elements of cardiovascular disease, comprising administering to a subject in need thereof a therapeutically effective amount of a dosage form comprising an active agent comprising one or more dopamine agonists and a pharmaceutically acceptable excipient, said dosage form being suitable for parenteral administration and exhibiting a pharmacokinetic profile with a plasma Tmax from about 1 to about 90 minutes after administration, a plasma drug concentration of at least 50% Cmax for a duration of about 90 to about 360 minutes, and a decrease in plasma level that may approximate first order elimination kinetics.

Problems solved by technology

Administration of dopamine agonists via the gut, however, is subject to several problems.

Absorption of dopamine agonists via the gastric or intestinal mucosa may also be problematic because dopamine agonists and their metabolites may cause undesirable side effects (e.g., nausea, vomiting, abdominal pain, constipation, and diarrhea).

The need to use increased dosages to account for first-pass metabolism in order to achieve therapeutic effectiveness increases the probability of undesirable GI side effects.

Production of stable parenteral formulations comprising ergot derivative dopamine agonists is particularly challenging, however, because ergot derivatives are extremely labile to light and water.

Images